Roberts Wealth Advisors LLC Has $5.10 Million Stock Holdings in Merck & Co., Inc. $MRK

Key Points

• Roberts Wealth Advisors LLC increased its holdings in Merck & Co., Inc. by 9.2% during the second quarter, now owning 64,444 shares valued at approximately $5.10 million.
• Merck reported earnings of $2.13 EPS for the last quarter, exceeding estimates, along with a revenue of $15.81 billion.
• The company announced a quarterly dividend of $0.81 per share, resulting in an annualized yield of 3.6%, with a payout ratio of 49.92%.

Roberts Wealth Advisors LLC raised its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 9.2% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 64,444 shares of the company's stock after acquiring an additional 5,453 shares during the period. Merck & Co., Inc. comprises 1.5% of Roberts Wealth Advisors LLC's portfolio, making the stock its 21st biggest position. Roberts Wealth Advisors LLC's holdings in Merck & Co., Inc. were worth $5,101,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Seamount Financial Group Inc. acquired a new stake in shares of Merck & Co., Inc. in the second quarter valued at approximately $360,000. SteelPeak Wealth LLC grew its position in Merck & Co., Inc. by 22.8% in the second quarter. SteelPeak Wealth LLC now owns 108,342 shares of the company's stock valued at $8,659,000 after purchasing an additional 20,104 shares in the last quarter. Mraz Amerine & Associates Inc. grew its position in Merck & Co., Inc. by 36.7% in the second quarter. Mraz Amerine & Associates Inc. now owns 3,728 shares of the company's stock valued at $295,000 after purchasing an additional 1,000 shares in the last quarter. Heck Capital Advisors LLC increased its stake in Merck & Co., Inc. by 853.2% in the 2nd quarter. Heck Capital Advisors LLC now owns 2,526 shares of the company's stock valued at $202,000 after buying an additional 2,261 shares during the last quarter. Finally, Motiv8 Investments LLC lifted its position in Merck & Co., Inc. by 12.8% during the 2nd quarter. Motiv8 Investments LLC now owns 13,272 shares of the company's stock worth $1,051,000 after buying an additional 1,508 shares in the last quarter. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. Trading Down 0.4%

Merck & Co., Inc. stock opened at $88.83 on Tuesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.17 and a current ratio of 1.42. The stock has a 50-day simple moving average of $82.96 and a 200 day simple moving average of $81.48. The stock has a market capitalization of $221.88 billion, a P/E ratio of 13.69, a PEG ratio of 0.92 and a beta of 0.37. Merck & Co., Inc. has a 52 week low of $73.31 and a 52 week high of $111.58.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its earnings results on Tuesday, July 29th. The company reported $2.13 EPS for the quarter, topping the consensus estimate of $2.03 by $0.10. The company had revenue of $15.81 billion during the quarter, compared to the consensus estimate of $15.92 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. Analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, October 7th. Investors of record on Monday, September 15th will be issued a dividend of $0.81 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.24 annualized dividend and a dividend yield of 3.6%. Merck & Co., Inc.'s payout ratio is presently 49.92%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on MRK shares. Berenberg Bank cut Merck & Co., Inc. from a "buy" rating to a "hold" rating and decreased their price objective for the company from $100.00 to $90.00 in a report on Wednesday, September 17th. Wells Fargo & Company decreased their price target on Merck & Co., Inc. from $97.00 to $90.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 30th. Morgan Stanley lowered their price target on Merck & Co., Inc. from $99.00 to $98.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 10th. Finally, Weiss Ratings reiterated a "hold (c-)" rating on shares of Merck & Co., Inc. in a research note on Saturday, September 27th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $104.31.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.